First 10 runs free
    Intelligence Feed event · Equity · 2026-11-08

    Eli Lilly Lifts Revenue Forecast by $5.5B as Novo Oral GLP-1 Sales Rise

    Question

    Eli Lilly Lifts Revenue Forecast by $5.5B as Novo Oral GLP-1 Sales Rise

    Direct answer

    Eli Lilly upgraded its full-year 2026 revenue guidance to $91 billion to $92 billion, representing a $5.5 billion boost over prior expectations of $85 billion to $87 billion. The upgrade was led by volume growth in incretin mimetics Mounjaro and Zepbound. Competitor Novo Nordisk similarly raised full-year projections after posting $810 million in quarterly revenue from its oral weight-loss formulation across 3 million prescriptions. The results confirm accelerating global adoption across both injectable and oral metabolic drug formats.

    Original publisher
    Market Ontology
    Evidence through
    2026-11-08
    Published
    2026-11-08
    Revision
    1 · 2026-11-08

    Cite as: Market Ontology, “Eli Lilly Lifts Revenue Forecast by $5.5B as Novo Oral GLP-1 Sales Rise”, revision 1, evidence through 2026-11-08. https://marketontology.com/market-events/2026-11-08/eli-lilly-lifts-revenue-forecast-by-5-5b-as-novo-oral-glp-1-sales-rise-15e33a

    EQUITY
    Eli Lilly Lifts Revenue Forecast by $5.5B as Novo Oral GLP-1 Sales Rise
    Eli Lilly upgraded its full-year 2026 revenue guidance to $91 billion to $92 billion, representing a $5.5 billion boost over prior expectations of $85 billion to $87 billion. The upgrade was led by volume growth in incretin mimetics Mounjaro and Zepbound. Competitor Novo Nordisk similarly raised full-year projections after posting $810 million in quarterly revenue from its oral weight-loss formulation across 3 million prescriptions. The results confirm accelerating global adoption across both injectable and oral metabolic drug formats.
    LLYNVO
    Impact
    80
    YESTERDAY
    SIG
    88%
    LLYNVO
    Eli Lilly Lifts Revenue Forecast by $5.5B as Novo Oral GLP-1 Sales Rise
    Eli Lilly upgraded its full-year 2026 revenue guidance to $91 billion to $92 billion, representing a $5.5 billion boost over prior expectations of $85 billion to $87 billion. The upgrade was led by volume growth in incretin mimetics Mounjaro and Zepbound. Competitor Novo Nordisk similarly raised full-year projections after posting $810 million in quarterly revenue from its oral weight-loss formulation across 3 million prescriptions. The results confirm accelerating global adoption across both injectable and oral metabolic drug formats.
    → Strong oral and injectable GLP-1 prescription uptake expands the commercial market, lifting LLY and NVO earnings growth outlooks.
    Impact
    Eli Lilly upgraded its full-year 2026 revenue guidance to $91 billion to $92 billion, representing a $5.5 billion boost over prior expectations of $85 billion to $87 billion. The upgrade was led by volume growth in incretin mimetics Mounjaro and Zepbound. Competitor Novo Nordisk similarly raised full-year projections after posting $810 million in quarterly revenue from its oral weight-loss formulation across 3 million prescriptions. The results confirm accelerating global adoption across both injectable and oral metabolic drug formats.
    Affected
    LLYNVO
    Transmission
    Strong oral and injectable GLP-1 prescription uptake expands the commercial market, lifting LLY and NVO earnings growth outlooks.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    LLYupward guidance revisions driven by GLP-1 volume accelerationUp1-4wEli Lilly raised 2026 revenue guidance to $91-92B from $85-87B.
    NVOcommercial oral pill market share expansion and guidance increaseUp1-4wNovo Nordisk oral weight-loss pill generated $810M in revenue with raised full-year guidance.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    Find trades for this development

    Screen tradable expressions of this catalyst against your horizon and constraints. Nothing is submitted without your review.

    First 10 runs free

    First 10 runs free

    See today's live cards

    Public pages are published 24 hours after the product shows them. The product shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open live cards